PD41: Benign Prostatic Hyperplasia: Surgical Therapy & New Technology V

Podium Session Moderator(s)

• MH

  Mitchell Humphreys, MD

  Professor and Chair, Dept of Urology
  Mayo Clinic
• AO

  Aria Olumi, MD (he/him/his)

  Chief of Urologic Surgery / Beth Israel Deaconess Med Center
  Beth Israel Deaconess Med Center/Harvard Medical School

Presentations:

• 7:00 AM – 7:10 AM CST

  PD41-01: Trends in the diagnostic and surgical management of Benign Prostatic Hyperplasia (BPH) in the United States: annual changes in the selection of treatment options and average costs differential for diagnostic/surgical technique
  

  Podium Presenter: Jin-Kyu Oh
• 7:10 AM – 7:20 AM CST

  PD41-02: 12-Month Outcomes from the first North American study of the Zenflow Spring System for the Treatment of Benign Prostatic Hyperplasia (BPH)
  

  Podium Presenter: Dean Sol Elterman, MD – University of Toronto
• 7:20 AM – 7:30 AM CST

  PD41-03: 12-Month Outcomes from a Randomized, Sham Controlled Study Evaluating a Novel Drug Coated Balloon for the Treatment of BPH
  

  Podium Presenter: Steven Abraham Kaplan, MD – Icahn School of Medicine at Mount Sinai
• 7:30 AM – 7:40 AM CST

  PD41-04: First in man clinical data through 24-months of a novel, minimally invasive treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia
  

  Podium Presenter: Thomas Hugh Lynch, MD, FRCS – St. James's Hospital
• 7:40 AM – 7:50 AM CST

  PD41-05: Second generation temporary implantable nitinol device (iTIND) impact on serum PSA level: results from a multicenter prospective study (MT-06-study)
  

  Podium Presenter: Daniele Amparore, PhD – University of Turin, Italy
• 7:50 AM – 8:00 AM CST

  PD41-06: Pooled analysis of 330+ subjects treated with the Prostatic Urethral Lift (PUL) reveals undertreatment impacts durability
  

  Podium Presenter: Claus Georg Roehrborn, MD (he/him/his) – UT Southwestern Medical Center
• 8:00 AM – 8:10 AM CST

  PD41-07: A novel outcomes categorization for current minimally invasive ejaculation-sparing treatments of benign prostatic hyperplasia: Results of a multicentric series
  

  Podium Presenter: Umberto Anceschi – IRCSS "regina Elena" National Cancer Institute
• 8:10 AM – 8:20 AM CST

  PD41-08: Device-Related Adverse Events During Benign Prostatic Hypertrophy Surgery: Review of the Manufacturer and User Facility Device Experience Database
  

  Podium Presenter: Ethan Nethery, MS,BS
• 8:20 AM – 8:30 AM CST

  PD41-09: Randomized Controlled Trial comparing Prostate Artery Embolization vs Open Prostatectomy: clinical and urodynamic assessment in a one year follow up.
  

  Podium Presenter: Bruno Lebani
• 8:30 AM – 8:40 AM CST

  PD41-10: Aquablation for BPH-related LUTS: functional and endoscopic results up to two years after the intervention
  

  Podium Presenter: Sabrina Titti De Cillis, MD
• 8:40 AM – 8:50 AM CST

  PD41-11: The Impact of Prostate Volumes (≤80 cc vs. > 80 cc) on Perioperative Outcomes and Risk of Retreatment in Patients Undergoing Aquablation: A Single-Center Study
  

  Podium Presenter: Michael Eppler, BA
• 8:50 AM – 9:00 AM CST

  PD41-12: Perioperative Complications and Outcomes of Patients Undergoing Aquablation for Benign Prostatic Hyperplasia: A Single Tertiary Referral Center Experience in 146 patients
  

  Podium Presenter: Alireza Ghoreifi, MD (he/him/his) – Duke University